Amneal Pharmaceuticals Launches First Respiratory Inhalers: Albuterol and Beclomethasone HFA Products Now Available

Key Takeaways

• Amneal Pharmaceuticals launched two FDA-approved respiratory inhalers: albuterol sulfate and beclomethasone dipropionate HFA aerosols
• These represent Amneal’s first metered-dose inhalation products, expanding the company’s portfolio into the respiratory medicine market
• Both products received FDA approval in 2025 and are now commercially available to patients with asthma and COPD

---

Amneal Enters Respiratory Market with Two New Inhalers

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) announced on April 14, 2026, the U.S. commercial launch of two respiratory medications: albuterol sulfate inhalation aerosol and beclomethasone dipropionate HFA inhalation aerosol. Both products received FDA approval in 2025 and mark the company’s inaugural entry into the metered-dose inhaler market.

Strategic Market Expansion

The launch represents a significant milestone for the Bridgewater, New Jersey-based pharmaceutical company, diversifying its product portfolio beyond traditional oral medications. Albuterol sulfate serves as a short-acting beta-agonist (SABA) bronchodilator for acute asthma symptoms, while beclomethasone dipropionate functions as an inhaled corticosteroid for long-term asthma control.

Market Impact and Patient Access

These widely prescribed respiratory treatments address critical needs in asthma and chronic obstructive pulmonary disease (COPD) management. The addition of generic alternatives typically increases patient access through competitive pricing, potentially reducing healthcare costs for the estimated 25 million Americans living with asthma.

Regulatory Pathway

Both inhalers underwent rigorous FDA review processes, including bioequivalence studies demonstrating therapeutic equivalence to reference products. The 2025 approvals followed comprehensive clinical testing to ensure safety and efficacy standards.

Future Implications

Amneal’s entry into respiratory therapeutics signals potential expansion into other specialized delivery systems and therapeutic areas. The company’s established manufacturing capabilities and distribution networks position it to compete effectively in the growing inhaled medication market, which analysts project will continue expanding due to increasing respiratory disease prevalence.

This launch strengthens Amneal’s position in the generic pharmaceutical sector while providing healthcare providers and patients with additional treatment options for respiratory conditions.

---

Frequently Asked Questions

What conditions do these new Amneal inhalers treat?

Albuterol sulfate treats acute asthma symptoms and bronchospasm, while beclomethasone dipropionate is used for long-term asthma control and prevention of symptoms.

When are Amneal’s respiratory inhalers available to patients?

Both albuterol sulfate and beclomethasone dipropionate HFA inhalers are now commercially available following their April 14, 2026 launch announcement.

How do these compare to existing inhaler treatments?

These are generic versions of widely prescribed respiratory medications, offering the same therapeutic benefits as brand-name products but typically at lower costs for patients and healthcare systems.

Related coverage

• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
• FDA approves Vertex’s Journavx as first non-opioid pain drug for acute pain
• FDA Approves Vertex’s First-in-Class Non-Opioid Pain Drug Journavx